Indication
Metastatic or Locally Advanced Unresectable Solid Tumors
3 clinical trials
5 products
Clinical trial
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Status: Active (not recruiting), Estimated PCD: 2024-05-20
Product
NiraparibProduct
M1774Clinical trial
An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor M1774 in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)Status: Recruiting, Estimated PCD: 2026-03-31
Product
AvelumabProduct
M4076Product
M1069Clinical trial
First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M1069 in Participants With Metastatic or Locally Advanced Unresectable Solid TumorsStatus: Terminated, Estimated PCD: 2023-05-09